Investing
The global data, analytics and AI company will use the Series J funds to invest in new AI products, complete acquisitions and expand its international go-to-market operations.
AI will transform healthcare with advances in multimodal technology, diagnostic imaging and automation, but its success depends on trust and seamless integration into workflows.
Some executives anticipate an acceleration of M&A activity as struggling startups seek exits, while others foresee more funding opportunities for companies with proven value in the sector.
Leaders weigh in on the digital health funding environment, women's health investments and how "AI washing" may influence capital raises.
The company touts that it recently surpassed 2.5 million rings sold and has seen its member base and revenue more than double over the past year.
The Series A investment brings the company's total capital raise to $20 million.
The funding brings the company's Series C funding round to a close and total capital raised to $155 million.
The company will use the funds to accelerate the development of its Ellipse Spinal Cord Stimulator Platform, used to treat chronic pain.
Tuva's CEO told MobiHealthNews that the company operates by "open-sourcing" the specialized knowledge needed to transform healthcare data and embedding that knowledge into an analytics-ready data model.
The company will fund and develop companies that focus on eight key areas in healthcare and create AI/genAI technologies that help advance those areas.